- Home
- GLOB vs ITCI Comparison
GLOB vs ITCI Comparison
Compare GLOB & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLOB
- ITCI
- Stock Information
- Founded
- GLOB 2003
- ITCI 2002
- Country
- GLOB Luxembourg
- ITCI United States
- Employees
- GLOB N/A
- ITCI N/A
- Industry
- GLOB EDP Services
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- GLOB Technology
- ITCI Health Care
- Exchange
- GLOB Nasdaq
- ITCI Nasdaq
- Market Cap
- GLOB 9.9B
- ITCI 8.7B
- IPO Year
- GLOB 2014
- ITCI N/A
- Fundamental
- Price
- GLOB $207.34
- ITCI $126.89
- Analyst Decision
- GLOB Buy
- ITCI Buy
- Analyst Count
- GLOB 20
- ITCI 13
- Target Price
- GLOB $232.15
- ITCI $100.31
- AVG Volume (30 Days)
- GLOB 345.3K
- ITCI 2.9M
- Earning Date
- GLOB 02-13-2025
- ITCI 02-20-2025
- Dividend Yield
- GLOB N/A
- ITCI N/A
- EPS Growth
- GLOB 7.25
- ITCI N/A
- EPS
- GLOB 3.84
- ITCI N/A
- Revenue
- GLOB $2,353,911,000.00
- ITCI $613,728,000.00
- Revenue This Year
- GLOB $17.70
- ITCI $48.41
- Revenue Next Year
- GLOB $14.19
- ITCI $38.26
- P/E Ratio
- GLOB $54.12
- ITCI N/A
- Revenue Growth
- GLOB 17.35
- ITCI 46.08
- 52 Week Low
- GLOB $151.68
- ITCI $62.78
- 52 Week High
- GLOB $251.50
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- GLOB 38.12
- ITCI 87.18
- Support Level
- GLOB $211.25
- ITCI $80.83
- Resistance Level
- GLOB $225.00
- ITCI $128.00
- Average True Range (ATR)
- GLOB 6.02
- ITCI 2.57
- MACD
- GLOB -1.24
- ITCI 4.45
- Stochastic Oscillator
- GLOB 21.42
- ITCI 97.65
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.